第六届董事会第十一次会议决议公告 《公司第六届董事会第十一次会议决议》 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载，误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）第六届董事会第十一次会议 于 2023 年 10 月 20 日以电子邮件、专人送达的方式通知各位董事，会议于 2023 年 10 月 30 日以现场、通讯表决的方式在南京江宁科学园科建路 699 号 A 楼 3102 会 议室召开。本次会议应到董事 9 人，实到董事 9 人。公司监事、高级管理人员列席 了会议。本次会议符合《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）等法律、行政法规、部门规章、规范 性文件和《公司章程》的相关规定。 会议由董事长陈庆财先生主持，经与会董事认真审议，一致形成如下决议： 一、审议通过《关于公司 2023 年第三季度报告的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 议案内容详见发布于巨潮资讯网（www.cninfo.com.cn）的《2023 年第三季度报 告》。 证券代码：002755 证券简称：奥 ...

证券代码：002755 证券简称：奥赛康 公告编号：2023-048 北京奥赛康药业股份有限公司 一、关于 ASKB589 注射液Ⅲ期关键性临床研究 本次获批开展的研究是一项评价 ASKB589 注射液（靶向 CLDN18.2 单克隆 抗体）或安慰剂联合 CAPOX（奥沙利铂和卡培他滨）及 PD-1 抑制剂一线治疗 CLDN18.2 阳性的不可切除的局部晚期、复发性或转移性胃及食管胃交界处腺癌 （G/GEJ）患者的有效性和安全性的 III 期临床研究。 同时靶向 CLDN18.2 和 PD-1, 可以通过提高先天免疫和适应性免疫能力, 为 治疗一线治疗局部晚期不可切除或转移性 HER2 阳性胃癌或 GEJ 腺癌患者提供 最新的治疗方案。 二、关于 ASKB589 注射液相关情况 ASKB589 注射液是 AskGene 自主研发的、拥有国际自主知识产权的 ADCC 增强型第二代抗 CLDN18.2 人源化单克隆抗体，研发进度处于全球前三家。目前 国内外尚无同靶点药物上市。 2023 年 6 月，AskGene 在第十五届国际胃癌大会（2023 IGCC）上以口头 汇 报 形 式 公 布 了 ASKB589 注 ...

（3）医保支付方式改革 | --- | --- | --- | --- | |----------|----------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002755 证券简称：奥赛康 北京奥赛康药业股份有限公司 投资者关系活动记录表 编号：2023-004 投资者关系活动类 □√特定对象调研 □分析师会议 别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □√其他 （电话会议） 参与单位名称 长江证券：伍云飞、单林 及人员姓名 东方证券、国新证券、中邮证券、嘉实基金、华夏基金、中信资管、 中海基金、中航基金、民生加银基金、华宝基金、兴业基金、宁波 银行理财、恒生前海基金、深圳前海基金、上银基金、湘财基金、 恒越基金、宝盈基金等 62 家机构 时间 2023 年 5 月 9 日 地点 电话会议 上市公司接待人员 总经理、董事会秘书 马竞飞 姓名 证券事务代表 王燕燕 一、公司基本情况介绍 介绍公司情况。 二、主要沟通问答 投资者关系活动主 问题 1、公司近年研发方向、研发投入等整体研发布局？ 要内容介绍 答：研发方向，未来几年仍然是聚焦在消化、抗肿瘤、抗感染、 慢性病四大治疗领域不变，除了公司已有的优势剂型注射剂之外， 公司积极拓展口服剂型产品，去年和今年已分别有多款口服制剂获 批上市。 研发投入，随着创新药项目陆续进入临床，预计未 ...

证券代码：002755 证券简称：奥赛康 北京奥赛康药业股份有限公司 投资者关系活动记录表 编号：2023-003 投资者关系活动类 □√特定对象调研 □分析师会议 别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □√其他 （电话会议） 参与单位名称 天风证券：李妞妞 及人员姓名 Point72 Hong Kong Limited 分析员：李大蔚、吴雪璐 时间 2023 年 5 月 5 日 地点 电话会议 上市公司接待人员 总经理、董事会秘书 马竞飞 姓名 证券事务部长 王燕燕 一、公司基本情况介绍 介绍公司基本情况。 二、主要沟通问答 问题 1、公司小分子创新药目前有哪些布局及进展？ 投资者关系活动主 答：公司已布局多款小分子创新药，其中主要产品有抗肿瘤创 要内容介绍 新药 ASK120067 片，是第三代 EGFR TKI，用于治疗 EGFR 突变非 小细胞肺癌（NSCLC），已申报生产。同步也在开展一线用药关于 存在 EGFR 敏感突变的初诊或手术治疗后复发的局部晚期或转移性 非小细胞肺癌的Ⅲ期临床研究试验。 抗肿瘤创新药 ASKC202 片，是一种强效、高选择性的口服小分 子 c- ...

重要内容提示： 北京奥赛康药业股份有限公司 2023 年第一季度报告 （一） 财务报表 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------| | | | | | 4. 企业自身信用风险公允价值 变动 | | | | 5. 其他 | | | | （二）将重分类进损益的其他综 合收益 | 4,388,827.24 | 1,658,711.40 | | 1. 权益法下可转损益的其他综 合收益 | | | | 2. 其他债权投资公允价值变动 | | | | 3. 金融资产重分类计入其他综 合收益的金额 | | | | 4. 其他债权投资信用减值准备 | | | | 5. 现金流量套期储备 | | | | 6. 外币财务报表折算差额 | 4,388,827.24 | ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year increase of 15%[13]. - The net profit attributable to shareholders was 300 million RMB, which is a 10% increase compared to the previous year[13]. - The company's operating revenue for 2022 was ¥1,872,572,189.84, a decrease of 39.72% compared to ¥3,106,666,569.36 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥225,825,439.44, representing a decline of 159.44% from ¥379,907,787.30 in 2021[19]. - The net cash flow from operating activities was -¥52,814,933.61 in 2022, down 109.30% from ¥567,707,650.56 in 2021[19]. - The total assets at the end of 2022 were ¥3,414,367,396.12, an 8.33% decrease from ¥3,724,750,010.48 at the end of 2021[19]. - The net assets attributable to shareholders decreased by 7.94% to ¥2,962,969,644.26 at the end of 2022 from ¥3,218,681,536.00 at the end of 2021[19]. - The basic earnings per share for 2022 was -¥0.24, a decline of 158.54% from ¥0.41 in 2021[19]. - The company reported a weighted average return on equity of -7.29% in 2022, down from 12.53% in 2021[19]. - The company achieved a revenue of CNY 1,872.57 million in 2022, a decrease of 39.72% year-on-year[56]. - The net profit attributable to shareholders was CNY -225.83 million, significantly impacted by a price drop of over 90% for 12 products selected in national centralized procurement[56]. Research and Development - Research and development expenses increased by 25% in 2022, totaling 150 million RMB, to support new product innovation[13]. - R&D investment reached CNY 722.97 million, accounting for 38.61% of total revenue, an increase of 74.58% year-on-year[57]. - The company has 43 projects in development, including 11 key innovative drugs such as ASK120067 and ASKG915[47]. - Six innovative drug clinical approvals were obtained during the reporting period, including ASKC202 and ASK0912[48]. - The company has submitted 469 patent applications, with 240 patents granted, including 174 Chinese invention patents[53]. - The company is focusing on high-barrier complex formulations and innovative drug development in oncology and chronic disease treatment[47]. - The company has established a national enterprise technology center and has been recognized as a national technology innovation demonstration enterprise[39]. - The company has launched a total of 15 products since 2021, including Posaconazole Injection and Dexamethasone Injection[45]. - The company is actively involved in research and development, with several projects in the pipeline[46]. - The company aims to enhance its innovation capabilities by focusing on small molecule targeted innovative drug development and expanding into tumor immunotherapy[151]. Market Expansion and Strategy - The company plans to launch three new products in 2023, focusing on innovative drug development and targeting a market size of 500 million RMB[13]. - Future guidance indicates a projected revenue growth of 20% for 2023, aiming for a total revenue of 1.44 billion RMB[13]. - The company is expanding its market presence in Southeast Asia, with plans to enter two new countries by the end of 2023[13]. - The company is actively exploring acquisition opportunities to expand its product portfolio and market reach[13]. - A strategic acquisition of a smaller pharmaceutical company is planned, which is expected to enhance the company's product portfolio and increase revenue by 200 million RMB annually[196]. - The company is expanding its digital marketing efforts by collaborating with third-party platforms such as Tmall and JD.com to enhance patient access to medications[100]. - The company is focusing on expanding its market presence through innovative drug development and strategic partnerships[120]. - The company aims to enhance its market presence through strategic product launches and expanding its therapeutic areas[44]. - The company is actively expanding its market presence through academic promotion activities and participation in large-scale exhibitions to increase brand awareness and market share[63]. Product Development and Innovation - The company focuses on the development of innovative drugs and high-tech generic drugs, with a strong presence in digestive, anti-tumor, anti-infection, and chronic disease treatment areas[38]. - The company has developed new products such as the Mesna Injection and the Erlotinib Capsule, expanding its oncology portfolio[45]. - The company’s products are designed to address unmet medical needs, particularly in oncology and chronic disease management[44]. - The company has launched a range of anti-infection products, including polymyxin E and posaconazole, to address the growing issue of antibiotic resistance[80]. - The company has introduced the first approved injectable Polymyxin E sulfate, which is critical for treating multi-drug resistant Gram-negative bacterial infections, especially in children[83]. - The company has successfully launched Lenvatinib capsules, breaking a decade-long monopoly in first-line treatment for liver cancer[88]. - The company has introduced Temozolomide injection, becoming the second domestic company to obtain approval for this innovative anti-tumor drug[89]. - The company is committed to high-quality development amidst economic challenges, enhancing overall management levels[96]. - The company aims to enhance product quality and market competitiveness through consistency evaluation, aligning with international standards[95]. Governance and Management - The company has established a complete independent business operation system, demonstrating autonomous management capabilities without reliance on the controlling shareholder[179]. - The company maintains an independent personnel management system, ensuring that all senior management personnel are exclusively employed by the company and do not hold positions in the controlling shareholder's enterprises[180]. - The company has a robust governance structure with a clear separation of powers among the shareholders' meeting, board of directors, and supervisory board, ensuring effective checks and balances[182]. - The company has an independent financial department and internal audit team, establishing a standardized accounting system and independent financial decision-making capabilities[183]. - The company is focused on sustainable development through its "health-based innovation" management model[189]. - The company has a new management team with key appointments including Ma Jingfei as the general manager and board secretary[188]. - The company is committed to maintaining a strong leadership team to drive future growth and innovation[188]. Challenges and Risks - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three accounting years[19]. - The company faces ongoing sales pressure due to national centralized procurement policies, leading to an average price drop of over 80% for proton pump inhibitors (PPIs)[156]. - The company has shifted to larger packaging to reduce costs, impacting sales and production volumes across several product lines[110]. - The company has experienced changes in its supervisory board, with new appointments made in 2022[188]. - The company has faced increased competition in 2022, particularly affecting the sales of "Aonoxian" due to the introduction of competing products[112]. Future Outlook - The company has set a future outlook with a revenue target of 1.8 billion RMB for 2023, indicating a projected growth of 20%[196]. - The company is investing in new technology for drug development, with a budget allocation of 100 million RMB for R&D in 2023[196]. - The management has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in costs by the end of 2023[196]. - The company aims to enhance its competitive edge by diversifying its product offerings in the oncology sector with new drug approvals expected in the near future[120].

本公司及董事会全体成员保证信息披露内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：002755 证券简称：奥赛康 公告编号：2023-017 北京奥赛康药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 北京奥赛康药业股份有限公司董事会 2023 年 4 月 28 日 北京奥赛康药业股份有限公司（以下简称"公司"）将于 2023 年 5 月 12 日 （星期五）下午 15：00—17：00 在全景网举办 2022 年度业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长陈庆财先生，董事、总经理、董事会 秘书马竞飞先生，独立董事吴晓明先生、财务总监韩涛先生，以及公司其他相关 人员。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 12 日（星期五）中午 12:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码 ...